betr Entertainment Limited (ASX:BBT) Announces Equity Raising and PointsBet Acquisition Proposal
betr Entertainment Limited (ASX:BBT) raises A$130 million to fund the acquisition of PointsBet, targeting over A$40 million in annual cost synergies.
Tag: Earnings Reports
Paradigm Biopharmaceuticals Ltd (ASX:PAR) Announces Phase 3 Trial Launch and Financial Update
Paradigm Biopharmaceuticals (ASX:PAR) announces the launch of its Phase 3 trial for knee osteoarthritis and the receipt of a $6.3 million R&D tax refund.
4DMedical Limited (ASX:4DX) Reports 103% Revenue Growth and Strategic Milestones
4DMedical Limited (ASX:4DX) achieves 103% YTD revenue growth and secures key strategic partnerships in Q3 FY2025.
Immutep Limited (ASX:IMM) Reports Q3 FY25 Milestones and Financial Position
Immutep Limited (ASX:IMM) announces significant clinical trial milestones and maintains a robust cash position in its Q3 FY25 report.
Health and Plant Protein Group Limited (ASX:HPP) Releases FY25 Q3 Activities Report
Health and Plant Protein Group Limited (ASX:HPP) releases FY25 Q3 report, highlighting cash flow and ongoing IRS repayment efforts.
BrainChip Holdings Ltd (ASX:BRN) Releases Q1 2025 Activities Report
BrainChip Holdings Ltd (ASX:BRN) releases Q1 2025 report, highlighting key partnerships and a solid financial position.
G8 Education Limited (ASX:GEM) Announces 2025 AGM Highlights
G8 Education Limited (ASX:GEM) reports a 14.8% EBIT increase and highlights strategic initiatives during its 2025 AGM.
Donaco International Limited (ASX:DNA) Reports Q3 FY2025 Results and Announces Share Acquisition Scheme
Donaco International (ASX:DNA) announces Q3 FY2025 results and a share acquisition Scheme Implementation Deed to strengthen its cash position.
Unibail-Rodamco-Westfield (ASX:URW) Announces Q1 2025 Trading Update
Unibail-Rodamco-Westfield (ASX:URW) reports strong Q1 2025 performance, confirms earnings guidance, and completes significant asset disposals.
Coventry Group Ltd (ASX:CYG) Announces Q3 FY25 Trading Update
Coventry Group Ltd (ASX:CYG) reports a 3.6% sales increase in Q3 FY25, despite a 41.1% drop in EBITDA, outlining strategic cost reductions for improved margins.